ACUR News Alert Acura Pharmaceuticals (ACUR) 0.55 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 11:11 AM

Acura Pharmaceuticals (ACUR) 0.55 $ACUR

17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)

Acura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain
Marketwired - Thu Feb 05, 5:15AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the launch of their second pseudoephedrine (PSE) product, NEXAFEDÂ® Sinus Pressure + Pain. NEXAFED Sinus Pressure + Pain [pseudoephedrine HCI 30mg + acetaminophen 325mg] is a meth-resistant immediate-release tablet that effectively relieves congestion due to colds and allergies, as well as pain and/or fever associated with colds and sinus headaches. NEXAFED Sinus Pressure + Pain will continue to utilize NEXAFED's unique, patented IMPEDEÂ® technology that disrupts the conversion of PSE into the dangerous drug methamphetamine (meth), and will be the first meth-resistant PSE combination sinus medicine available.
ACUR: 0.55 (+0.01)

Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 10.60 (+0.58), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ACUR: 0.55 (+0.01)

Egalet up on HAL study
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:38AM CST

EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)

Direction of Market Influences: New Coverage of Acorda, Acura Pharmaceuticals, Adamas, Adamis and Addus HomeCare
PR Newswire - Wed Jan 14, 6:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Acorda (NASDAQ: ACOR), Acura Pharmaceuticals (NASDAQ: ACUR), Adamas (NASDAQ: ADMS), Adamis (NASDAQ: ADMP), and Addus HomeCare (NASDAQ: ADUS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADMS: 16.98 (+0.03), ADUS: 21.57 (+0.18), ADMP: 6.50 (-0.01), ACOR: 36.14 (-0.51), ACUR: 0.55 (+0.01)

Acura inks deal with Egalet to commercialize oxycodone product
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:17AM CST

EGLT: 10.60 (+0.58), ACUR: 0.55 (+0.01)

Acura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Marketwired - Thu Jan 08, 5:00AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that the Company has entered into a Collaboration and License Agreement (the "Agreement"

with Egalet US, Inc. and Egalet Ltd. (together "Egalet", subsidiaries of Egalet Corporation (NASDAQ: EGLT), which is also a party to the Agreement with obligations thereunder) granting Egalet exclusive worldwide rights to commercialize Acura's immediate release oxycodone hydrochloride tablets product which incorporates Acura's patented AversionÂ® (abuse-deterrent) Technology platform. The licensed product, formerly known as Oxecta, will be marketed by Egalet under the name OXAYDO(TM). OXAYDO is FDA approved in 5mg and 7.5mg strengths for the treatment of acute and chronic moderate to severe pain.
EGLT: 10.60 (+0.58), ACUR: 0.55 (+0.01)

Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - Thu Dec 25, 11:41AM CST

MNK: 115.01 (+2.51), BDSI: 14.92 (+0.93), ENDP: 84.01 (+1.12), EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)

Acura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy
Marketwired - Tue Dec 23, 5:00AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine hydrochloride (HCl)], Acura's next generation pseudoephedrine with methamphetamine-resistant IMPEDE technology, in all Kmart in-store pharmacies nationwide (http://www.pharmacytimes.co m/sap-news/Kmart-Pharmacy-Takes-Step-to-Battle-Methamphetamine).
ACUR: 0.55 (+0.01)

Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations
Marketwired - Mon Dec 08, 5:30AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has been issued U.S. Patent No. 8,901,113 by the United States Patent and Trademark Office.
ACUR: 0.55 (+0.01)

FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST

MNK: 115.01 (+2.51), EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)

Acura Pharmaceuticals' CEO Robert Jones on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 1:23PM CST

ACUR: 0.55 (+0.01)

Acura Pharmaceuticals beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:33PM CST

ACUR: 0.55 (+0.01)

Acura Pharmaceuticals Announces Third Quarter 2014 Financial Results
Marketwired - Mon Nov 03, 3:31PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2014.
ACUR: 0.55 (+0.01)

Acura Pharma reports November 3
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:03AM CDT

ACUR: 0.55 (+0.01)

Acura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4, 2014
Marketwired - Tue Oct 28, 10:11AM CDT
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for the third quarter 2014 following the close of financial markets on Monday, November 3, 2014. The Company will host a conference call to discuss the results on Tuesday, November 4, 2014 at 8:30 a.m. ET.
ACUR: 0.55 (+0.01)

OTC Daily Alert Stock Watch - Acura Pharmaceuticals, Inc., (NASDAQ: ACUR)
WorldStockWire - Sat Oct 18, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ACUR: 0.55 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

Gourmia Introduces Ceramic-Coated Air Fryer at Costco

A New Era for Home Cooking with Gourmia Stepping into the kitchen appliances arena with a dash of innovation, Gourmia has launched its first ceramic-coated air fryer, and it’s weaving its way exclusively onto the shelves of Costco. Now, it’s not just about frying anymore; it’s about adding style, efficiency, and a touch of healthy living to your countertop. But much...

Omega Point's MCP Secures Anthropic Verification

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

A1 Refrigeration Keeps East Texas Homes Comfortable Year-Round

Homeowners in East Texas would agree: the last thing you want is your HVAC system throwing a tantrum when you're in the thick of a scorching summer or a biting winter. That's where A1 Refrigeration & Air Conditioning steps in, making sure folks in Jasper, Brookeland, and Kirbyville aren't left sweating bullets or shivering in their boots. Preventive Maintenance: A...

Oracle Announces AI-Driven QuickStart Platform Launch

NetSuite's AI-First Step into the Market Well, here's the NYSE stirring the pot with Oracle NetSuite's fresh announcement—an AI-first platform called QuickStart. Sounds like they've got their sights set on early-stage tech startups, banking on those little guys to plug into AI tools they've already got in their toolkit. Claude, ChatGPT—these aren't new kids on the...

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...